Using a proteomic immunoassay on blood and cerebrospinal fluid (CSF) samples from a total of 231 patients with multiple sclerosis (MS) and 96 healthy controls, researchers identified two plasma and 10 CSF biomarkers that could aid early detection of disease and prognosis; together, the biomarkers showed a sensitivity of 85.7% and specificity of 73.5% in detecting MS, and, with further validation, could help monitor treatment response as well as progression of inflammation and neurodegeneration in patients, according to the authors.
Article # 19-12839: " Inflammation-related plasma and CSF biomarkers for multiple sclerosis," by Jesse Huang et al.
MEDIA CONTACT: Ingrid Kockum, Karolinska Institute, Stockholm, SWEDEN; e-mail: ingrid.kockum@ki.se
###
Proceedings of the National Academy of Sciences